The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy

Authors

Lana Hamieh, Washington University School of Medicine in St. Louis
Rachel L Beck, Washington University School of Medicine in St. Louis
Valerie H Le, Washington University School of Medicine in St. Louis
James J Hsieh, Washington University School of Medicine in St. Louis

Journal

Clinical Genitourinary Cancer

Publication Date

8-1-2020

Volume

18

Issue

4

First Page

252

Last Page

257

Document Type

Open Access Publication

DOI

10.1016/j.clgc.2020.03.003

Rights and Permissions

Hamieh L, Beck RL, Le VH, Hsieh JJ. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Clin Genitourin Cancer. 2020 Aug;18(4):252-257.e2. doi: 10.1016/j.clgc.2020.03.003. Copyright 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Hamieh, Lana; Beck, Rachel L; Le, Valerie H; and Hsieh, James J, "The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy." Clinical Genitourinary Cancer. 18, 4. 252 - 257. (2020).
https://digitalcommons.wustl.edu/oa_4/291